The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020

Journal of Translational Medicine

Vernon K. Sondak¹  Igor Puzanov²  Paolo A. Ascierto³  Jeffrey E. Gershenwald⁴  Michael B. Atkins⁵  Jeffrey S. Weber⁶  Iman Osman⁷  Alexander M. Eggermont⁸  Jeffrey A. Sosman⁹  Jean-Jacques Grob^1,10  Omid Hamid^1,11  Corrado Caracò^1,12  Hussein A. Tawbi^1,13 

[1] Department of Cutaneous Oncology, Richard M. Schulze Family Foundation, Moffitt Cancer Center;Department of Medicine, Roswell Park Comprehensive Cancer Center;Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”;Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center;Georgetown-Lombardi Comprehensive Cancer Center;Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine;New York University Langone Medical Center;Princess Maxima Center and University Medical Center Utrecht;Robert H Lurie Comprehensive Cancer Center of Northwestern University;Service de Dermatologie et Cancérologie CutanéeHôpital de la Timone, Aix-Marseille Université;The Angeles Clinic and Research Institute;Unit of Melanoma and Skin Tumor Surgery, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”;University of Texas MD Anderson Cancer Center;

关键词: Melanoma;    Staging;    Immunotherapy;    Anti-PD-1;    Anti-CTLA-4;    Targeted therapy;   

DOI  :  10.1186/s12967-021-02808-3

来源: DOAJ

【 摘 要 】

Abstract The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

【 授权许可】

Unknown